|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 2985 Drew Street |
Address2 |
|
City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Clearwater |
State | FL |
Zip Code | 33759 |
Country | USA |
|
5. Senate ID# 400855514-12
|
||||||||
|
6. House ID# 418910000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: John Learn |
Date | 10/20/2023 1:23:56 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Hosted roundtable with Congresswoman Kathy Castor to discuss issues pertaining to drug and medical supply shortages. Advocated for PAHPA reauthorization to include additional information on drug supply and production, specifically for pediatric drugs.
Met with Congressman Gus Bilirakis and advocated for protection of the 340B drug pricing program. Specifically, we requested assistance in changing a policy implemented in the FY 24 IPPS rule pertaining to the Medicaid DSH calculation and using uncompensated care pool days under Floridas Low Income Pool Program. Also hosted roundtable with Congressman Bilirakis on the current struggles in the nursing industry.
Met with House Ways & Means majority staff to discuss expansion of the current hospital-at-home waiver program. Also met with staff to build relationships for Congressman Scott Franklin, Congresswoman Laurel Lee, Congresswoman Kathy Castor, and Senator Marco Rubio. Discussion included scope of BayCare, concerns about legislation (HR5378) on site neutral payments particularly pertaining to drug administration and cosponsorship of the SAVE Act to codify assault on hospital staff as a federal crime. Met with Congresswoman Lunas staff in district.
Responded to an RFI from CMS on a future episodic based payment model, advocated for expansion of the acute hospital-at-home waiver among other changes to drive innovation and equity in healthcare.
Provided formal comment letters for the following proposed rules:
-CY 2024 Physician Fee Schedule - CMS-1784-P
-Remedy for the 340B-Acquired Drug Payment Policy for Calendar Years 2018-2022 - CMS 1793-P
-CY 2024 Home Health Prospective Payment System - CMS-1780-P
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
In the comment letters submitted for CMS-1784-P, CMS-1793-P, and CMS-1780-P BayCare advocated for adequate reimbursement for providers. Particularly for CMS-1780-P, where cuts extending the past two years threaten the access to care for Medicare beneficiaries by underpaying home health providers.
For the RFI on a Future Episodic-based Payment Model, BayCare stressed the improvements possible if hospital-at-home offered via the CMS waiver were expanded to include observation level patients.
BayCare also cautioned about the lack of adequate funding for drug administration, particularly infusion, and the detriment that could have for continuity of care for those that are uninsured, being removed from state Medicaid plans during redetermination, or insured but unable to manage copay responsibilities.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Discussed current activity in Congress on 340B and the lack of accountability on drug manufacturers as well as the programming BayCare provides the community with the 340B savings. These programs include the Medication Assistance Program to ensure all in our community have access to the prescription drugs they require (we take referrals from anyone, not just BayCare patients/providers) and the Pharmacy Transition of Care team that helps improve medication adherence and transition/care coordination for those returning home with various prescriptions. Also discussed the concern with the removal of 1115 waiver days or uncompensated care pool days in the inclusion of the Medicaid DSH calculation for the purposes of 340B qualification.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Learn |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |